PRKAA1 and diabetes mellitus: By stimulating AMPK, inhibitors of purine metabolism, which are often used to treat inflammatory diseases and other conditions associated with glucose dysregulation [8, 12, 13, 14, 15, 16], could provide additional therapeutic benefit, especially over those immunosuppressants and antineoplastics that increase the risk of diabetes [17, 18].